Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study
Language English Country England, Great Britain Media print-electronic
Document type Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
29572505
PubMed Central
PMC6087720
DOI
10.1038/s41375-018-0023-2
PII: 10.1038/s41375-018-0023-2
Knihovny.cz E-resources
- MeSH
- Adenine analogs & derivatives MeSH
- Humans MeSH
- Lymphoma, Mantle-Cell drug therapy pathology MeSH
- International Agencies MeSH
- Survival Rate MeSH
- Follow-Up Studies MeSH
- Piperidines MeSH
- Prognosis MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
- Pyrazoles administration & dosage MeSH
- Pyrimidines administration & dosage MeSH
- Sirolimus administration & dosage analogs & derivatives MeSH
- Salvage Therapy * MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial, Phase III MeSH
- Multicenter Study MeSH
- Research Support, Non-U.S. Gov't MeSH
- Randomized Controlled Trial MeSH
- Comparative Study MeSH
- Names of Substances
- Adenine MeSH
- ibrutinib MeSH Browser
- Piperidines MeSH
- Pyrazoles MeSH
- Pyrimidines MeSH
- Sirolimus MeSH
- temsirolimus MeSH Browser
1st Dept Medicine Charles University General Hospital Prague Czech Republic
APHP Saint Louis Hospital Hemato oncology Diderot University Paris France
Departement Oncologie UZ Gent Ghent Belgium
Department of Hematology Jagiellonian University Krakow Poland
Department of Medicine 3 Klinikum der Universität München LMU Munich Germany
Instituto Biosanitario de Salamanca Hospital Clinico Universitario Salamanca Salamanca Spain
Janssen Research and Development Leiden The Netherlands
Janssen Research and Development Raritan NJ USA
Klinikum der Ruprechts Karls Universität Heidelberg Med Klinik u Poliklinik 5 Heidelberg Germany
Plymouth University Medical School Plymouth UK
Seoul St Mary's Hospital Seocho gu Seoul South Korea
See more in PubMed
Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009;27:512–8. doi: 10.1200/JCO.2008.16.8435. PubMed DOI
IMBRUVICA® [US prescribing information]. Sunnyvale, CA: Pharmacyclics, LLC; Horsham, PA: Janssen Biotech, Inc.; 2017.
Wang M, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–16. doi: 10.1056/NEJMoa1306220. PubMed DOI PMC
Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv62–iv71. doi: 10.1093/annonc/mdx223. PubMed DOI
Dreyling M, Jurczak W, Jerkeman M, Santucci Silva R, Rusconi C, Trneny M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international randomised, open-label, phase 3 study. Lancet. 2016;387:770–8. doi: 10.1016/S0140-6736(15)00667-4. PubMed DOI
Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24:4867–74. doi: 10.1200/JCO.2006.07.9665. PubMed DOI
Goy A, Sinha R, Williams ME, Kalayoglu Besisik S, Drach J, Ramchandren R, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013;31:3688–95. doi: 10.1200/JCO.2013.49.2835. PubMed DOI PMC
Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, et al. Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27:3822–9. doi: 10.1200/JCO.2008.20.7977. PubMed DOI
Jurczak W, Ramanathan S, Giri P, Romano A, Mocikova H, Clancy J et al. Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma. Leuk Lymphoma. 2018;59:670–8. PubMed
Wang M, Lee HJ, Thirumurthi S, Chuang HH, Hagemeister FB, Westin JR, et al. Chemotherapy-free induction with ibrutinib-rituximab followed by shortened cycles of chemo-immunotherapy consolidation in young, newly diagnosed mantle cell lymphoma patients: a phase II clinical trial. Blood. 2016;128:147. doi: 10.1182/blood-2016-05-716167. PubMed DOI
